ERBB2 and neoplasm: Trastuzumab radiolabelled with 64Cu, 89Zr or 111In has demonstrated the potential for HER2 imaging by identifying known and/or previously unknown tumour lesions in patients, but lacks sensitivity compared with conventional imaging owing to a long half-life and high blood pool activity [12–14].